Zealand Pharma presented new preclinical data on ZP2929 in disease models for diabetes and obesity

ZP2929 caused a greater loss in body weight and fat mass as compared to treatment with liraglutide, a marketed GLP-1 agonist

29-Jun-2011 - Denmark

Zealand Pharma A/S has presented new data from preclinical studies with ZP2929, a glucagon/GLP-1 dual agonist drug candidate in preclinical development for the treatment of type 2 diabetes and obesity. ZP2929 was discovered by Zealand Pharma and recently global rights to the drug candidate were licensed to Boehringer Ingelheim as part of a global licence and collaboration agreement between the two companies to advance novel compounds for the treatment of Type 2 diabetes and obesity.

The preclinical data on ZP2929 was presented in a poster session at the American Diabetes Association (ADA)’s 71st Scientific Sessions in San Diego, California from 24 – 28 June 2011 entitled: “The new glucagon-GLP-1 dual agonist ZP2929 in combination with long-acting insulin improves glycemic control without causing weight gain in db/db mice”

Treatment of Type 2 diabetic patients with long-acting insulin analogues for control of blood glucose is known to be associated with weight gain. In preclinical models, ZP2929 has been shown to improve glycemic control while decreasing body weight.

The results presented show that in a well-known preclinical disease model of diabetes, the combination of ZP2929 with long-acting insulin over a 21-day period resulted in a significant reduction in blood glucose. Moreover, the combination with ZP2929 over the same period of time resulted in stable body weight whereas treatment with long-acting insulin alone resulted in weight gain. A second study in a preclinical model for obesity, showed that treatment with ZP2929 alone resulted in not only a significant weight loss but also a greater weight loss than seen with liraglutide, a marketed GLP-1 agonist.

https://www.bionity.com/en/news/133273/zealand-pharma-presented-new-preclinical-data-on-zp2929-in-disease-models-for-diabetes-and-obesity.html